US/UK/Canada

Share

Pick a time period -
Tags ( Active)

DanCann Pharma A/S: DanCann Pharma Announces Outcome of Directed Issues to Board and Management

COPENHAGEN, Denmark, 10 December 2024 – The Board of Directors of DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, announces the outcome of the directed issues of shares and warrants to Jeppe Krog Rasmussen, Carsten Trads, Jes Lunde and Christian Carlsen as decided by the Extraordinary General Meeting on 10 December 2024 (the ”Directed Issues”). All 200,000,000 shares and 100,000,000 warrants of series TO3 were subscribed for and allocated in accordance with the decision of the Extraordinary General Meeting.The Directed Issues

DanCann Pharma A/S: Minutes of Extraordinary General Meeting

[Pressemeddelelser | Dancann Pharma] held in DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”) on Tuesday, 10 December 2024 at 09:00 am (CET) On 10 December 2024 at 9:00 am (CET), an extraordinary general meeting was held in the Company at the Company’s address, Rugvænget 5, 6823 Ansager, Denmark. The agenda for the extraordinary general meeting was as follows: Proposed resolution to elect one (1) new additional member of the board 1. of directors (proposed by the board of directors)     Proposed resolution to issue shares to members of the executive

DanCann Pharma A/S: Agreement Reached on Permanent Medicinal Cannabis Scheme in Denmark

COPENHAGEN, Denmark, 29 November 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, is pleased to announce that the Danish Government (comprising Socialdemokratiet, Venstre og Moderaterne) and Socialistisk Folkeparti, Liberal Alliance, Danmarksdemokraterne, Enhedslisten, Dansk Folkeparti and Alternativet, have reached an agreement on 28 November 2024 to make the current Pilot Programme for medicinal cannabis permanent.A Permanent Framework for Medicinal Cannabis Under this permanent scheme, patients experiencing positive

DanCann Pharma A/S Recommends Experienced Politician and Senior Government Official to Join the Board of Directors

COPENHAGEN, Denmark, 25 November 2024 – DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”), a Danish company powered by cannabinoids, is pleased to announce its nomination of Jes Lunde to join its Board of Directors at the upcoming Extraordinary General Meeting, scheduled for 10 December 2024.Jes Lunde brings a wealth of experience to the Company, having served as a Member of the Danish Parliament (Folketinget) from 1984 to 2001, representing the Socialist People’s Party (SF). During his tenure, he held prominent roles, including Group Chairman and Member of the Finance

NOTICE OF EXTRAORDINARY GENERAL MEETING IN DANCANN PHARMA A/S

The Board of Directors hereby convenes an extraordinary general meeting of DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”), to be held on Tuesday, 10 December 2024 at 09:00 am (CET)at DanCann Pharma A/S’ address, Rugvænget 5, 6823 Ansager, Denmark The agenda for the extraordinary general meeting is as follows: Proposed resolution to elect one (1) new additional member of the board of 1. directors (proposed by the board of directors)  Proposed resolution to issue shares to members of the executive board and 2. board of directors of the Company without pre-

DanCann Pharma A/S: The Board of Directors has resolved on directed share issues of DKK 4.5 million and proposal of directed share issues of DKK 0.4 million

COPENHAGEN, Denmark, 25 November 2024 – The Board of Directors of DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, has today decided to carry out directed issues of shares and warrants to investors pursuant to an authorisation granted by the general meeting, cf. clause 6.4 of the articles of association. The investors have subscribed for all shares and warrants in the directed issues. Through the directed issues of shares and warrants, the Company will initially receive approximately DKK 4.5 million before deduction of transaction

DanCann Pharma A/S Publishes Q3-2024 Report: Steady Growth in Medicinal Cannabis Prescriptions Signals Promising Future for Patients

COPENHAGEN, Denmark, 22 November 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the third quarter (Q3) of 2024. The Q3-2024 report is available as an attached document to this press release and at www.dancann.com.SUMMARY: GROUP KEY FIGURES Q3-2024 +-----------+----------+----------+----------+----------+-------------------+|DKK 1,000 |01/07/24 |01/07/23 |01/01/24 |01/01/23 |01/01/23 - 31/12/23|| |- 30/09/24|- 30/09/23|- 30/09/24|- 30/09/

DanCann Pharma A/S: The Danish Government Proposes Permanent Scheme for Prescription-Based Medicinal Cannabis for Danish Patients

COPENHAGEN, Denmark, 19 November 2024 – DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”), a Danish company powered by cannabinoids, hereby announces that the Danish government has expressed its intention to make the Pilot Programme for prescription-based medicinal cannabis permanent. This proposal will be presented today by the Minister of the Interior and Health, Sophie Løhde, during negotiations with the political parties supporting the initiative. The decision is based on a recent evaluation that highlights a significant increase in the number of prescriptions filled,

DanCann Pharma A/S: Capital reduction in DanCann Pharma A/S is completed

The capital reduction in DanCann Pharma A/S as resolved on an extraordinary general meeting held on 7 October 2024 has been completed today, 5 November 2024, following expiry of a 4-week notice period ("proklama").As set out in press release published on 7 October 2024, at an extraordinary general meeting in DanCann Pharma A/S held on 7 October 2024 it was resolved to reduce the share capital of the Company by nominally DKK 13,869,911.106 from nominally DKK 15,411,012.34 to nominally DKK 1,541,101.234 by transfer of the amount to a special reserve fund (in Danish: henlæggelse til særlig

Minutes of extraordinary general meeting

held in DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”)(Please note: The capital reduction (item 1) and the resulting amendments of the articles of association cannot be completed before expiration of the 4-week notice period (“proklama”) which commences today. Attached are updated articles of association without the capital reduction (effective today) and updated articles of association including the capital reduction). On 7 October 2024 at 09:00 am (CET), an extraordinary general meeting was held in the Company at the Company’s address, Rugvænget 5, 6823 Ansager, Denmark.

DanCann Pharma A/S: Calls for an Extraordinary General Meeting regarding New Authorizations and Reduction of Share Capital in Preparation for Reverse Stock Split

COPENHAGEN, Denmark, 24 September 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, announces further details regarding the notice of an extraordinary general meeting ("EGM") and the matters to be discussed.DanCann Pharma has called for an EGM to be held on Monday, 7 October 2024 at 09:00 am (CET), based on the recommendation of the Board of Directors. At the EGM, it will be proposed to reduce the Company’s nominal share capital by transferring the amount to a special reserve fund. The capital reduction is completed by way

NOTICE OF EXTRAORDINARY GENERAL MEETING IN DANCANN PHARMA A/S

The Board of Directors hereby convenes an extraordinary general meeting of DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”), to be held on Monday, 7 October 2024 at 09:00 am (CET) at DanCann Pharma A/S’ address, Rugvænget 5, 6823 Ansager, Denmark The agenda for the extraordinary general meeting is as follows: Proposed resolution to reduce the Company's share capital by transfer of 1. the amount to a special reserve fund (in Danish: henlæggelse til særlig  reserve) by way of reduction of the nominal value per share of the Company, including consequential

DanCann Pharma A/S: Number of Reported Suspected Adverse Reactions Drops by Two-Thirds in 2023 Despite 72% Growth in the Medicinal Cannabis Pilot Programme

COPENHAGEN, Denmark, 18 September 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby provides a status on the ongoing monitoring of the Pilot Programme for medicinal cannabis.As part of the ongoing monitoring of the Pilot Programme for medicinal cannabis, the Danish Medicines Agency has released a report on the reporting of suspected adverse reactions, cannabis end-products, and the consumption status for 2023. In 2023, the Danish Medicines Agency received a total of three reports of suspected adverse reactions

DanCann Pharma A/S: Quarterly CEO Reflection

COPENHAGEN, Denmark, 14 August 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces the CEO’s reflections following the publication of the Company’s Q2-2024 report.CEO, Jeppe Krog Rasmussen, comments:   Financials: Record revenue and positive EBITDA DanCann Pharma closed Q2-2024 with a record revenue of DKK 3.86 million. For H1-2024, this resulted in a further record revenue of approximately DKK 4.55 million. Comparing this to the revenue of DKK 2.90 million for H1-2023, we have amassed an increase of

DanCann Pharma A/S Publishes Q2-2024 Report: Record Revenue and First-Ever Positive EBITDA

COPENHAGEN, Denmark, 14 August 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the second quarter of 2024. The Q2-2024 report is available as an attached document to this press release and at www.dancann.com.SUMMARY: GROUP KEY FIGURES Q2-2024 +-----------+----------+----------+----------+----------+-------------------+|DKK 1,000 |01/04/24 |01/04/23 |01/01/24 |01/01/23 |01/01/23 - 31/12/23|| |- 30/06/24|- 30/06/23|- 30/06/24|- 30/06/23|

DanCann Pharma A/S announces last day for trading in temporary shares

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, RUSSIA, BELARUS, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. COPENHAGEN, Denmark, 3 July 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces that the rights issue of shares that was

DanCann Pharma A/S announces outcome of the Rights Issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, RUSSIA, BELARUS, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. COPENHAGEN, Denmark, 27 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces the outcome of the rights issue of shares

DanCann Pharma A/S: Last day of subscription of shares in the ongoing Rights Issue is 20 June 2024 on Nordnet Bank and Avanza Bank

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SINGAPORE, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.   COPENHAGEN, Denmark, 19 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announces that Thursday, 20 June 2024 at 13:59 CET, is the last day

DanCann Pharma A/S: Solid growth in the Rx portfolio

COPENHAGEN, Denmark, 18 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby provides an update on its current portfolio and expectations for the year ahead.Key highlights from the portfolio[1] and pipeline[2]: · Growth in 2023: Achieved a sales growth of +40% year-over-year (YoY) in pharmacy sales. · Sales volume: This growth equated to +14,000 packages of medicine. · 2024 projections: The Company aims to further increase the current Rx portfolio sales volume to 20,000 packages in 2024, representing a

DanCann Pharma A/S: Germany trends – prescriptions for medicinal cannabis positively influenced by new legalization

COPENHAGEN, Denmark, 14 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, announces key insights into the recent legalization of cannabis in Germany ("CanG"), which came into effect on April 1, 2024.Key highlights from CanG: · Declassification: Cannabis is no longer classified as a narcotic but as a regular (off-label-use) medicine. · Elimination of risk assessment: No longer required to assess risks such as possible addiction when prescribing medicinal cannabis. · Simplified prescription process: Abolition

DanCann Pharma A/S: Submits applications for FLS03 and FLS04 to expand portfolio

COPENHAGEN, Denmark, 12 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, has formally submitted applications for two additional medicines to enrich the existing portfolio with the Danish Medicines Agency under the Danish Pilot Programme for medicinal cannabis.Submission of two new applications: · FLS04, CBD-granulate · FLS05, THC-flos The applications encompass two new medicines, poised to complement the current trio of approved products (Bedrocan®, Bedica®, and Bediol®). These include a THC-dominant

DanCann Pharma A/S: The subscription period of DanCann Pharma’s Rights Issue begins today

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SINGAPORE, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURESCOPENHAGEN, Denmark, 11 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announces that the subscription period of DanCann Pharma’s rights issue of

DanCann Pharma A/S: Publishes Q1-2024 Report

COPENHAGEN, Denmark, 01 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the first quarter of 2024 (“Q1-2024”). The Q1-2024 report is available as an attached document to this press release and at www.dancann.com.Summary: Group Key Figures Q1-2024 DKK 1,000 01/01/24 01/01/23 01/01/23 – 31/12/23 01/01/22 – 31/12/22 –31/03/24 –31/03/23 Net sales: 702 620 6,073 5,708 Operating -2,645 -4,

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media

Rss